#
Asceniv Intravenous
  • Treatments
  • Primary Immunodeficiency Syndrome

Asceniv (Intravenous)

Generic name:immune globulin-slra (intravenous route) [ i-MUNE-GLOB-ue-lin-- slra ]
Drug class:Immune globulins

Medically reviewed by Drugs.com. Last updated on Jan 25, 2022.

Commonly used brand name(s)

In the U.S.

  • Asceniv

Available Dosage Forms:

  • Solution

Therapeutic Class: Immune Serum

Uses for Asceniv

Immune globulin-slra injection contains antibodies that make your immune system stronger. It is used for patients who have primary humoral immunodeficiency (PI), including congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and other severe combined immune system problems.

This medicine is to be given only by or under the supervision of your doctor.

Before using Asceniv

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of immune globulin-slra injection in children younger than 3 years of age. Safety and efficacy have not been established.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of immune globulin-slra injection in the elderly. However, elderly patients are more likely to have age-related liver, kidney, or heart problems, which may require caution and an adjustment in the dose for patients receiving this medicine.

Breastfeeding

There are no adequate studies in women for determining infant risk when using t...